Nephros (NASDAQ:NEPH) Shares Down 2.8% – Time to Sell?

Nephros, Inc. (NASDAQ:NEPHGet Free Report)’s share price traded down 2.8% during mid-day trading on Monday . The company traded as low as $1.60 and last traded at $1.60. 5,861 shares were traded during trading, a decline of 22% from the average session volume of 7,553 shares. The stock had previously closed at $1.65.

Analyst Upgrades and Downgrades

Separately, Benchmark restated a “speculative buy” rating and issued a $5.00 price target on shares of Nephros in a report on Tuesday, November 12th.

Read Our Latest Analysis on NEPH

Nephros Stock Performance

The company has a market capitalization of $16.59 million, a price-to-earnings ratio of -17.49 and a beta of 1.19. The company has a 50 day moving average price of $1.55 and a 200 day moving average price of $1.72.

Nephros (NASDAQ:NEPHGet Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.02 EPS for the quarter. Nephros had a negative return on equity of 11.39% and a negative net margin of 6.86%. The firm had revenue of $3.52 million during the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Nephros stock. Dimensional Fund Advisors LP bought a new position in shares of Nephros, Inc. (NASDAQ:NEPHFree Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 17,631 shares of the company’s stock, valued at approximately $37,000. Dimensional Fund Advisors LP owned approximately 0.17% of Nephros at the end of the most recent reporting period. Institutional investors and hedge funds own 41.10% of the company’s stock.

Nephros Company Profile

(Get Free Report)

Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.

Read More

Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.